vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $53.00.
Several analysts have commented on the stock. BTIG Research reiterated a "buy" rating and set a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Wall Street Zen upgraded shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. HC Wainwright reiterated a "buy" rating and set a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. Roth Mkm assumed coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a "buy" rating and a $58.00 target price for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of vTv Therapeutics in a report on Friday, March 27th.
Check Out Our Latest Report on VTVT
Hedge Funds Weigh In On vTv Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $221,000. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $731,000. Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP grew its holdings in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock valued at $3,463,000 after buying an additional 51,000 shares during the period. Institutional investors and hedge funds own 17.51% of the company's stock.
vTv Therapeutics Stock Performance
Shares of vTv Therapeutics stock opened at $38.33 on Wednesday. The firm has a fifty day moving average of $36.50 and a two-hundred day moving average of $32.40. The stock has a market capitalization of $151.02 million, a price-to-earnings ratio of -11.44 and a beta of 0.40. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51. The business had revenue of ($0.02) million for the quarter.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
